DEWB AG Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG

NOXXON PHARMA NV LISTS ITS SHARES ON ALTERNEXT PARIS

Business news for the stock market

Berlin, Germany, 28 September 2016 (pta011/28.09.2016/09:42) - NOXXON Pharma N.V. ("NOXXON" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on cancer treatment development, today announces the listing of its ordinary shares (the "Shares") on Alternext Paris. The Shares will trade under the symbol ALNOX (ISIN: NL0012044762).

Company highlights

- Lead product candidate NOX-A12 is positioned as a combination therapy in cancer: The Company believes that the future of cancer treatment lies in finding optimal combinations of drugs to fight cancer in multiple ways. The Company believes its lead product candidate NOX-A12 is well positioned to become a combination partner for a wide range of cancer treatments, based on its complementary mode of action targeting the tumor microenvironment. As part of a combination, the Company believes NOX-A12 has broad potential in both solid and hematological tumors.

- NOX-A12 may be a key partner for IO (immuno-oncology) agents: The Company's first priority is development of NOX-A12 in advanced solid tumors that do not respond to checkpoint inhibitor monotherapy, and the Company has mapped out further potential for the compound in brain cancer and multiple myeloma. NOXXON has generated promising pre-clinical and clinical data, including recent animal data showing synergy with a checkpoint inhibitor as well as recent phase 2a trials in multiple myeloma and a second hematological cancer that showed a safety profile that supports further development and first signs of efficacy. The Company believes that its planned clinical study in advanced solid tumors positions the Company for a clear route to market of NOX-A12.

- Second clinical-stage tumor microenvironment drug candidate: In addition to NOX-A12, the Company has another clinical-stage asset: NOX-E36. This compound has completed a 75 patient exploratory Phase 2a in diabetic nephropathy and is now being studied for applications in cancer therapy following recent promising clinical results obtained by another compound acting on the same pathway as part of a combination therapy in pancreatic cancer. The Group believes that these data suggest significant potential to increase efficacy in this solid tumors by tumor microenvironment modulation of the pathway targeted by NOX-E36.